Epidermal growth factor receptor (EGFR) mutations and the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement are the two most-prevalent druggable targeting categories in NSCLC patients [1]. The gene discussed is EML4; the disease is non-small cell lung carcinoma.